ARV-393
ARV-393 is a potent and orally active BCL6 PROTAC degrader. ARV-393 induces ubiquitination of BCL6 and its subsequent degradation by the proteasome. ARV-393 has the potential for the research of advanced non-hodgkin lymphoma[1][2][3].
Product Specifications
CAS Number
2851885-95-3
UNSPSC
12352005
Target
BCL6; PROTACs
Type
Reference compound
Related Pathways
Immunology/Inflammation; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/arv-393.html
Purity
99.75
Solubility
DMSO : 20 mg/mL (ultrasonic)
Smiles
ClC1=CN=C(N2CCC(O[C@@H]3C[C@@H](N4CCC(C5=C(F)C(CN(C6CCC(NC6=O)=O)C7=O)=C7C=C5)CC4)C3)CC2)N=C1NC8=CC(C=C(OCC(NC)=O)C(N9C(C)C)=O)=C9C=C8
Molecular Formula
C46H53ClFN9O7
Molecular Weight
898.42
References & Citations
[1]Sherman D. Abstract ND05: The discovery of ARV-393, a potent, orally bioavailable BCL6 targeting PROTAC® for the treatment of Non-Hodgkin’s Lymphoma[J]. Cancer Research, 2024, 84 (7_Supplement) : ND05-ND05.|[2]Paolo F. Caimi, et al. Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood. 2024, 144: 6505.|[3]Paolo Caimi, et al. Abstract PO-010: Trial in Progress: Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin Lymphoma. Blood Cancer Discov. 2024. 5 (3_Supplement) : PO-010.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
EIA05096Ch 1 Kit
Chicken Complement 3 split product (C3SP) ELISA Kit
Sign In for Pricing
View Details 